1. Home
  2. DGLY vs NLSP Comparison

DGLY vs NLSP Comparison

Compare DGLY & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DGLY
  • NLSP
  • Stock Information
  • Founded
  • DGLY N/A
  • NLSP 2015
  • Country
  • DGLY United States
  • NLSP Switzerland
  • Employees
  • DGLY N/A
  • NLSP N/A
  • Industry
  • DGLY Radio And Television Broadcasting And Communications Equipment
  • NLSP Biotechnology: Pharmaceutical Preparations
  • Sector
  • DGLY Technology
  • NLSP Health Care
  • Exchange
  • DGLY Nasdaq
  • NLSP Nasdaq
  • Market Cap
  • DGLY 4.1M
  • NLSP 12.4M
  • IPO Year
  • DGLY N/A
  • NLSP 2021
  • Fundamental
  • Price
  • DGLY $2.26
  • NLSP $2.10
  • Analyst Decision
  • DGLY
  • NLSP
  • Analyst Count
  • DGLY 0
  • NLSP 0
  • Target Price
  • DGLY N/A
  • NLSP N/A
  • AVG Volume (30 Days)
  • DGLY 115.1K
  • NLSP 275.3K
  • Earning Date
  • DGLY 08-15-2025
  • NLSP 07-22-2025
  • Dividend Yield
  • DGLY N/A
  • NLSP N/A
  • EPS Growth
  • DGLY N/A
  • NLSP N/A
  • EPS
  • DGLY N/A
  • NLSP N/A
  • Revenue
  • DGLY $18,596,715.00
  • NLSP N/A
  • Revenue This Year
  • DGLY N/A
  • NLSP N/A
  • Revenue Next Year
  • DGLY N/A
  • NLSP N/A
  • P/E Ratio
  • DGLY N/A
  • NLSP N/A
  • Revenue Growth
  • DGLY N/A
  • NLSP N/A
  • 52 Week Low
  • DGLY $1.93
  • NLSP $1.30
  • 52 Week High
  • DGLY $265.00
  • NLSP $15.59
  • Technical
  • Relative Strength Index (RSI)
  • DGLY 25.38
  • NLSP 46.61
  • Support Level
  • DGLY $2.17
  • NLSP $2.20
  • Resistance Level
  • DGLY $2.32
  • NLSP $3.08
  • Average True Range (ATR)
  • DGLY 0.15
  • NLSP 0.25
  • MACD
  • DGLY 1.10
  • NLSP -0.06
  • Stochastic Oscillator
  • DGLY 20.93
  • NLSP 8.40

About DGLY Digital Ally Inc.

Digital Ally Inc produces digital video imaging and storage products for use in law enforcement, security, and commercial applications. Its products are an in-car digital video/audio recorder contained in a rear-view mirror for use in law enforcement and commercial fleets. It can integrate electronic, radio, computer, and multi-media technologies to create solutions to address needs in a variety of other industries and markets, including mass transit, school buses, taxicab, and military. The company sells its products directly to law enforcement agencies, security organizations, and consumer and commercial fleet operators both domestically and internationally through third-party distributors. Its segments include Video Solutions, Revenue Cycle Management, and Entertainment.

About NLSP NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Share on Social Networks: